Biotech award-winner in search of new capital
‘You have to give before you can get’ seems to be a rule of business for Immudex – a biotech company which constantly tweaks its development-costs to ensure its continued survival.
The biotech company Immudex, which - among other things - works on a more reliable borrelia-test than the one currently on the market, is already attempting to secure fresh capital to launch new development projects. But the apparent strategy of the company is still to ensure its continued operation and not to bet everything on development projects – and investors like this approach, says company founder and CEO Henrik Pedersen.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
